Fig. 4

Comparison of serum DIDO1-Abs, FOXJ2-Abs, and CPSF2-Abs levels between HDs and patients with chronic kidney disease (CKD). Serum antibody levels against GST-DIDO1:1-275 protein (a), bFOXJ2-426 peptide (e), and bCPSF2-607 peptide (i) were compared between HDs and patients with CKD types 1, 2, and 3. The P values of CKD types 1, 2, and 3 versus HD controls are shown. Results are presented as described in the legend of Fig. 2. P values versus HD specimens are shown. The details are shown in Table 4. Responses to DIDO1-Abs (b–d), FOXJ2-Abs (f–h), and CPSF2-Abs (j–l) were also evaluated using the ROC analysis and are summarized in Table 5